Retatrutide 4 mg is an investigational metabolic peptide attracting significant attention in obesity and weight‑management research. Unlike earlier therapies, Retatrutide acts as a triple receptor agonist, targeting GLP‑1, GIP, and glucagon receptors simultaneously. This multi‑pathway approach is designed to influence appetite regulation, glucose control, energy expenditure, and fat m... https://sites.up.edu/tabletalk/2022/04/14/emma-callanan-class-of-2025/comment-page-546/#comment-38455